NEW YORK – AstraZeneca and Daiichi Sankyo on Monday said they will seek regulatory approval for the antibody-drug conjugate Enhertu (trastuzumab deruxtecan) in HER2-positive early breast cancer ...
NEW YORK – Taiho Oncology and Cullinan Therapeutics are advancing the next-generation EGFR inhibitor zipalertinib in two indications, for EGFR-mutant non-small cell lung cancer patients who are ...
The funding will support the firm's pipeline of mRNA and gene correction therapies, including an investigational inhaled mRNA therapy under testing for cystic fibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback